A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone
- Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- 14 Feb 2024 Planned End Date changed from 21 Dec 2023 to 21 Dec 2024.
- 19 Jun 2023 Planned End Date changed from 21 May 2023 to 21 Dec 2023.
- 02 Jun 2022 Planned End Date changed from 21 May 2022 to 21 May 2023.